One of Finland’s Leading Telecom Service Providers, DNA, Selects Universal Electronics for Its Award-Winning Android TV Controller
20.6.2022 16:02:00 EEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices, has been selected by Finland-based DNA to debut UEI’s award-winning Android TV remote control, UEI KITA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220620005313/en/
Finland's DNA Selects Universal Electronics for its Award-Winning Android TV Controller. The UEI KITA controller for Android TV has received the prestigious “RedDot” award for its outstanding fit, form and function. The elegant design fits perfectly in users’ hands due to its slim rechargeable battery that makes the product much thinner and easier to hold than ordinary remote controls. (Photo: Business Wire)
The UEI KITA controller for Android TV has received the prestigious “RedDot” award for its outstanding fit, form and function. The elegant design fits perfectly in users’ hands due to its slim rechargeable battery that makes the product much thinner and easier to hold than ordinary remote controls. In an effort to design sustainable, environmentally friendly products, the UEI KITA remote control can potentially save dozens of disposable batteries throughout its lifetime in typical consumer use scenarios, compared to ordinary remotes with disposable batteries, by fast-charging via a USB-C cable only a few times per year.
The product’s advanced technology includes Bluetooth Smart and Infrared wireless connectivity; high-precision voice control; an innovative backlit keypad; and UEI’s QuickSet Cloud® platform, which is the world’s only automated device discovery technology to control TV and audio receivers without user intervention. And while packed with technology, by using premium materials and soft coatings the UEI KITA attains an excellent look and a velvety tactile feel with every click.
As the largest cable operator and the leading pay-TV provider in cable networks with over 4 million mobile and fixed network subscribers, DNA has a track record of introducing consumer-friendly technology to a wider audience. “Adding the UEI KITA remote control to our product showcase allows DNA to surpass our customers’ expectations in next-generation, environmentally friendly technology, and make their lives less complicated,” says DNA Product Development Director Ville Partanen.
“It’s a natural fit for DNA to be the first provider to introduce UEI’s flagship Android controller to its customer base,” explains Kuldip Johal, UEI’s Vice President of Sales for Video Service Providers. “The UEI KITA’s consumer-centric, advanced technology directly aligns with DNA’s focus on sustainability, as well its relentless effort to launch a user experience that is extremely easy and looks and feels premium.”
For information on ordering the UEI KITA Android remote control from DNA, click here.
About Universal Electronics Inc.
Universal Electronics Inc. (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices, designs, develops, manufactures, ships and supports hardware and software control and sensor technology solutions. UEI partners with many Fortune 500 customers, including Comcast, Vivint Smart Home, Samsung, LG, Sony, and Daikin to serve video, telecommunications, security service providers, television, smart home, and HVAC system manufacturers. For over 35 years, UEI has been pioneering breakthrough innovations such as voice control and QuickSet cloud, the world’s leading platform for automated set-up and control of devices in the home. For more information visit www.uei.com.
QuickSet® is a registered trademark of Universal Electronics Inc.
All trademarks appearing herein are the property of their respective owners.
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release; the purchasing by DNA of the UEI KITA remote products identified in this release in the quantities anticipated by management; the performance of the battery saving features over time in the UEI KITA remote, the continued penetration and growth of UEI QuickSet, Android remote platforms, voice recognition technology and other products and consumer technologies identified in this release; and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005313/en/
Contact information
Eva Delgado
Eva.delgado@uei.com
714-987-8209
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom